Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Author information

Affiliations

  • 1. Surgery Branch, National Cancer Institute, Bethesda, MD 20892.
      Authors
    • Rosenberg SA 1
    (1 author)

The New England Journal of Medicine, 01 Dec 1988, 319(25):1676-1680
https://doi.org/10.1056/nejm198812223192527 PMID: 3264384 

A comment on this article appears in "Tumor-infiltrating lymphocytes and interleukin-2 in melanomas." N Engl J Med. 1989 May 25;320(21):1418-9.

Abstract 

Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

Full text links 

Read article at publisher's site: https://doi.org/10.1056/nejm198812223192527

References 

Articles referenced by this article (26)

Show 10 more references (10 of 26)

Citations & impact 

Impact metrics

1,232
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/4336432
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/4336432

Article citations

Go to all (1,232) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.